Asthma is a respiratory disease symptomatically characterized by repeated stridor and paroxysm due to airway contraction. The number of patients with this disease is gradually increasing, especially in the industrial countries. Although a number of drugs have been used for the treatment of asthma, a new type of anti-asthmatic drug is strongly desirable due to the unsatisfactory effectiveness as well as adverse effects of existing drugs. Since asthma is believed to be a chronic inflammatory disease based on recent studies in pathophysiology, a drug, which can inhibit the inflammatory process, may offer a new therapeutic approach for curing for asthma patients. Therefore, compounds possessing inhibitory activities for both airway contraction and airway inflammation may become a novel therapeutic agent for asthma.
It is known that phosphodiesterase (PDE) can regulate some cell functions through the hydrolysis of cAMP. 1) Within the phosphodiesterases, as at least ten subclasses, [2] [3] [4] PDE 4 has recently attracted much attention due not only to their roles in airway contraction and airway inflammation proved by rolipram, [5] [6] [7] [8] an authentic PDE 4 inhibitor, but also their locations in the airway smooth muscles and infiltrated cells. [9] [10] [11] So far, several PDE 4 inhibitors mainly derived from rolipram have been developed and some of them were proved to be effective for the treatment of asthma. 12) However, adverse effects such as emesis and poor pharmacological profiles have made them difficult to undergo further clinical development.
In order to remove these drawbacks, the creation of a novel class of PDE 4 inhibitors structurally different form rolipram would be necessary. Therefore, random screening was performed using our chemical library, and YM-10335 13) was found to possess a structure completely different from rolipram. Unfortunately, YM-10335 has some problems such as a weak activity, moderate selectivity (PDE 2 vs. 4) and poor membrane permeability. To improve these biological profiles of YM-10335, several modification of YM-10355 were performed. As a consequence, several compounds with good in vitro as well as in vivo activities have been found and are going further extensive pharmacological evaluations. Herein, the syntheses, structure-activity relationships, and biological activities of a series of 1,8-naphthyridin-2(1H)-one derivatives are described.
Synthesis A procedure for the preparation of YM-10335 and the 5,7-disubstituted 1,8-naphthyridine derivatives have been reported. 13) In order to optimize the yields and to provide new compounds, the synthetic route was modified (Chart 1).
The 7-substituted derivatives without 5-substituents were synthesized by the methods shown in Chart 2. The 3-cyano or 3-carboxyl-2-chloropyridine derivatives were treated with the corresponding Grignard reagents, substituted by amines, acetylated, followed by aldol condensation and dehydration that produced the naphthyridine compounds (7) . In the case of the 4-(2-chlorophenyl)-and 4-(3-bromophenyl)-derivatives, no desired compound was obtained by the Grignard re- In order to develop novel and orally active phosphodiesterase (PDE) 4 inhibitors, random screening was performed using our chemical library to find YM-10335 possessing the 1,8-naphthyridin-2(1H)-one skeleton which is a completely different structure from rolipram. In this report, the syntheses and structure-activity relationships of the YM-10335 derivatives were described. Some compounds showed selective inhibitory activities for PDE 4 derived from human peripheral blood cells and no effect on the other PDE types (1, 2, 3, 5). The inhibition of the tumor necrosis factor-alpha (TNF-a a) release in vitro and the carrageenan-induced pleurisy in rats were also described.
Synthetic Studies on
action. Therefore, another synthetic route for compound 6 was adopted as shown in Chart 3. Namely, the corresponding benzonitriles were converted to benzoylacetonitrile 8, hydrolyzed by polyphosphoric acid (PPA), and cyclized using acetal to give pyridone 9. Compound 9 was tosylated and substituted by amines similar to the chlorides (5) in Chart 2.
The 7-ethyl (7o, p) or 7-propyl (7q) derivatives were afforded by the further alkylation of the 7-methyl derivative (Chart 4).
Although the naphthyridine-2-one derivative without a 1-substituent (14) was not able to be synthesized by the above methods, we prepared it as shown in Chart 5. The 3-position of 2-pivaroylaminopyridine (11) 14) was lithiated by n-butyllithium, then benzoylated using N-methoxy-N-methylbenzamide to give the benzoylpyridine derivative (12) . Compound 12 was treated with the lithium enolate of tert-butyl acetate and subsequently cyclized to 4-phenyl-1,8-naphthyridine-2-one (14) .
As shown in Chart 6, the carbonyl group at the 2-position of 4a was converted to the thiocarbonyl group using phosphorus pentasulfide to give 15, and the double bond at the 3,4-position of 4a was reduced by the platinum dioxide-catalyzed hydrogenation to afford 16.
The quinolone derivative (19) was synthesized using the methods of Chart 7. Ethylaniline was treated with 1 under basic conditions and cyclized to the quinolone 18, which was alkylated to obtain compound 19.
Results and Discussion
In order to assess the structure-activity relationships, the compounds synthesized above were evaluated for their in vitro inhibitory activity against human leukocyte PDE 4.
At first, the effect of each methyl group in YM-10335 was investigated. As shown in Table 1 , removal of all the methyl groups or two methyl groups at the 5-and 7-positions of YM-10335 showed no inhibitory activity (14, 7a). Compound 7j with methyl groups at both of the 1-and 7-positions on the naphthyridine ring was found to show increased inhibitory activity. Moreover, the 5-substituent should be unnecessary for inhibition since the activity of 7j was better than that of YM-10335. To ascertain this expectation, replacement of the 5-methyl group in 4b with an ethyl group (4c) was performed. The inhibitory activity of 4c was decreased, therefore, the 1,7-substituted 1,8-naphthyridine derivatives are favorable to show PDE 4 inhibitory activity. Because of the steric interaction of the 5-substituent with the benzene ring at the 4-position, the 5-substituted 1,8-naphthyridine derivatives are unable to adopt a conformation ap-propriate for PDE 4 inhibition. Because it was found that the 1,7-disubstituted derivatives are favorable for showing activity, each substituent was modified. As shown in Table 2 , replacement of the of the 1-methyl group in 7j with an ethyl group (7b) increased the inhibitory activity up to the nanomolar level, however replacement with the n-and i-propyl groups only provided a moderate increase (7k, 7l). As for the 1-substituents, the ethyl group is crucial for PDE 4 inhibition and very sensitive for modification.
Replacement of the 7-methyl group in 7c with an ethyl group (7p) slightly increased the inhibitory activity, whereas replacement with a n-propyl group (7q) resulted in significantly reduced the activity (Table 4 ). In the case of the 7-substituent, a small alkyl group such as a methyl or ethyl is favorable.
Secondly, the effect of the substituent on the benzene ring at the 4-position of the naphthyridine on the PDE 4 inhibitory activity was examined (Table 3) . The introduction of a chlorine atom at the meta position (7c) increased the potency over 7b by almost 5-6 fold, whereas, its introduction at the ortho (7m) or para (7d) position slightly reduced the activity. Various meta substituents were introduced, and the bromo-(7n), methyl-(7f), and nitro-(7i) derivatives showed potent activities, while the fluoro-(7e) and methoxy-(7g) derivatives showed slightly reduced activities. Based on these results, there was no significant difference between the electron-donating and electron-withdrawing groups. It is unclear why the trifluoromethyl group (7h) showed low activity. Among the halogen substituents, the fluorine derivative (7e) showed low activity compared with the other halogen groups, therefore, an unfavorable interaction seems to be present between the PDE 4 enzyme and fluorine atom.
Finally, the effects of the nitrogen atom at the 8-position and the pyridone moiety of the 1,8-naphthyridine ring system on the PDE 4 inhibitory activity were examined. As shown in Table 5 , replacement of the carbonyl group in compound 4a with the thiocarbonyl group (15) slightly reduced the activity. This slight difference is caused by the hydrogen bonding acceptor ability based on the difference in the bond length and electron-withdrawing activity between the carbonyl and thio- carbonyl groups. Reduction of the double bond in the pyridone moiety (16) dramatically reduced the potency. Although it is assumed that the existence of p electron should be necessary, it is the main reason of this result that appropriate spatial positioning of the phenyl group at 4-position relative to 1,8-naphthyridine ring system is essential for PDE 4 inhibition. Exchanging the nitrogen atom of 7o for a carbon atom (19) resulted in the loss of potency. Since the basicity of this nitrogen atom is not so high, this might occur due to the difference as a hydrogen bonding acceptor. It is also possible to consider that the repulsion between the newly generated hydrogen at the 8-position and the 1-substituents would be unfavorable. Another experiment is needed for this clarification.
These facts described above suggested that three factors affected the PDE 4 inhibitory activity in this series. First, the appropriate size of the substituents such as the methyl and ethyl groups at the 1-and 7-positions on the 1,8-naphthyridin-2-one structure is necessary for inhibitory activity. Second, the benzene ring at the 4-position of the naphthyridine has the appropriate position and direction. And third, the nitrogen atom at the 8-position and carbonyl moiety of the 1,8-naphthyridine ring system function as an acceptor of the hydrogen bonding against the PDE 4 enzyme.
The pharmacophore model of many PDE 4 inhibitors was reported by Crespo and co-workers, 15) in which PDE 4 inhibitors related to the nitraquazone structure possess three hydrogen bond acceptors and three aromatic regions. However, our 1,8-naphthyridine derivatives possess two hydrogen bond acceptors and two aromatic regions. From these points of view, the 1,8-naphthyridine compounds were novel types of PDE 4 inhibitors.
Six compounds showing potent PDE 4 inhibitory activities, as well as YM-10335, rolipram, and CDP-840, were evaluated for their PDE isozyme selectivities and lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNF-a) release in vitro (Table 6 ). All compounds showed good selectivities of more than 500 times for PDE 4 against other PDE isozymes. In the test of the TNF-a release, they showed good inhibitory activities except for 7b.
Furthermore, five compounds (7c, f, n, o, p), possessing IC 50 values less than 100 nM in the test of the TNF-a release, were tested in the carrageenan-induced pleurisy model for evaluation of their ability to inhibit cell infiltration and oral effectiveness (Table 7) . Three compounds (7c, n, p) showed 1054 Vol. 50, No. 8 a) Data of in vitro experiment are expressed as mean from two separate experiments, and the individual experiment was performed in triplicate. The method of measurement is described in Experimental.
inhibitory activities and their ED 30 values were 15, 11, and 15 mg/kg, respectively, whereas 7f and 7o showed no oral activity.
In conclusion, a novel class of PDE 4 inhibitors, YM-10335, was found by chemical file screening and structural modification of YM-10335 led us to discover highly potent and selective compounds. These YM-10335 derivatives also showed potent inhibitory activities of the in vitro TNF-a release and in vivo carrageenan-induced pleurisy model. Further modification and pharmacological evaluations are now in progress.
Experimental
Chemistry Melting points were determined on a Yanaco micro-melting apparatus and are uncorrected. Proton magnetic resonance ( 1 H-NMR) spectra were obtained in CDCl 3 or dimethylsulfoxide-d 6 (DMSO-d 6 ) using a JEOL JNM-EX90, JNM-EX400, JNM-GX500 or JNM-A500 spectrometer. Chemical shifts are recorded in parts per million (d), downfield relative to tetramethylsilane as the internal standard. Mass spectra (MS) were recorded on a JEOL JMS-DX300 or a Hitachi M-80 mass spectrometer. Elemental analyses were carried out on Yanaco MT-3 or MT-5 CHN analyzer and a Yokogawa IC 7000S Ion Chromatoanalyzer. Chromatographic separations were performed using a silica gel column (Wakogel C-200). Analytical thinlayer chromatography (TLC) was carried out on precoated glass plates (Merck Kieselgel 60F254).
6-Amino-1-ethyl-4-phenyl-2(1H)-pyridone (3b): Ethyl 4-cyano-3-phenyl-3-butenoate 13) (2, 29.0 g, 0.13 mol) and 28% ethylamine-methanol solution (41 g) were added to a methanol solution (120 ml) of sodium (4.1 g, 0.17 mol), and the mixture was stirred for 20 h at room temperature. The reaction solution was poured onto ice water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was washed with diethyl ether-diisopropyl ether to provide 3b (16.5 g, 57%) as a gray solid.
A mixture of diphosphorus pentoxide (10.7 g) and phosphoric acid (5 ml) was stirred at 140°C until it became transparent. 3b (2.14 g, 10 mmol) and acetylacetone (1.1 ml, 10 mmol) were then added to this solution, and the mixture was stirred at 140°C for 3 h. The reaction solution was poured onto ice water, made alkaline by adding a 1 N sodium hydroxide aqueous solution and then extracted with ethyl acetate. After drying the organic layer with anhydrous magnesium sulfate, the magnesium sulfate was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (toluene-ethyl acetate) to give 4a (2.10 g, 76%). Recrystallization from diisopropyl ether-hexane provided an analytical sample as colorless minute prisms, mp 113-114°C. 1 General Procedure B. Grignard Reaction with 2-Chloro-6-methylnicotinic Acid 2-Chloro-3-(3-fluorobenzoyl)-6-methylpyridine (5e): To a stirred solution of 3-bromochlorobenzene (46 g, 262 mmol) in anhydrous tetrahydrofuran (400 ml) was slowly added magnesium turnings (6.3 g, 262 mmol). After the exothermal reaction was completed, the reaction mixture was cooled to Ϫ20°C, and 2-chloro-6-methylnicotinic acid (21.1 g, 122 mmol) was added all at one time. The reaction mixture was stirred overnight at room temperature, diluted with saturated ammonium chloride aqueous solution, and extracted by ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was chromatographed on silica gel using chloroform as an eluent to provide 5 h (11.0 g, 36%) as a colorless oil. 1 -6-methyl-3-(3-nitrobenzoyl) pyridine (5i) 5b (3.00 g, 12.9 mmol) dissolved in concentrated sulfuric acid (40 ml) was cooled to below 5°C, then fuming nitric acid (1.0 ml) was slowly added dropwise, followed by stirring for 30 min. The reaction solution was poured into ice-water, neutralized with a sodium hydroxide aqueous solution and then extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. After removing the magnesium sulfate by filtration, the solvent was evaporated under reduced pressure and the resulting residue was washed with ethyl acetate-diisopropyl ether to give 5i (1.81 g, 51%) as a solid. 1 
2-Chloro
. General Procedure D 3-(2-Chlorophenyl)-3-oxopropanenitrile (8a): A solution of 2-chlorobenzonitrile (50.0 g, 363 mmol), acetonitrile (21.0 ml, 402 mmol) and tert-butanol (4.0 ml, 42 mmol) in tetrahydrofuran (200 ml) was added dropwise to a mixture of sodium hydride/60% oil dispersion (16.0 g, 400 mmol) and tetrahydrofuran (200 ml), and the mixture was stirred at 40°C for 8 h. The reaction mixture was poured onto ice water and extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. The magnesium sulfate was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was then dissolved in chloroform (350 ml) and then 3 N hydrochloric acid (300 ml) was added. The mixture was stirred at room temperature for 4 h and organic layer was separated. The aqueous layer was extracted with chloroform and the chloroform layer was combined. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. Magnesium sulfate was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography hexane-ethyl acetate as the eluent and the resulting solid was washed with chloroform/hexane to provide 8a (23.6 g, 36%) as a colorless solid. 
).
General Procedure E 3-(2-Chlorobenzoyl)-6-methyl-2-pyridone (9a): A mixture of 8a (20.0 g, 111 mmol) and 75% diphosphorus pentoxide (100 ml) was stirred at 100°C for 2 h. The reaction solution was poured onto ice water and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate aqueous solution and dried over anhydrous magnesium sulfate. The magnesium sulfate was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethanol (250 ml) and mixed with 1,1-dimethoxy-3-butanone (20 ml, 151 mmol) and sodium ethoxide (9.0 g, 132 mmol). The mixture was stirred overnight under reflux. The reaction mixture was poured onto icewater and extracted with chloroform. The organic layer was washed with brine and dried over anhydrous magnesium sulfate. After removing the magnesium sulfate by filtration, the solvent was evaporated under reduced pressure and the resulting residue was washed with ether to give 9a (24.2 g, 84%) as a solid. 1 
. General Procedure F 3-(2-Chlorobenzoyl)-6-methyl-2-pyridyl 4-Methylbenzenesulfonate (10a): A mixture of 9a (20.0 g, 80 mmol), dichloroethane (250 ml), p-toluenesulfonyl chloride (16.8 g, 88 mmol), triethylamine (12.2 ml, 88 mmol), and 4-dimethylaminopyridine (980 mg, 8 mmol) was stirred for 2 h at room temperature. The reaction mixture was subsequently washed with water, 1 N hydrochloric acid, and saturated sodium bicarbonate aqueous solution. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was chromatographed on silica gel using hexane-ethyl acetate as the eluent to provide 10a (30.9 g, 96%) as a syrup. General Procedure G. Substitution by Alkylamines 3-(2-Chlorobenzoyl)-2-ethylamino-6-methylpyridine (6m): A mixture of 10a (8.0 g, 20 mmol), 70% ethylamine aqueous solution (10 ml), and toluene (30 ml) was stirred for 1.5 h at 100°C in a sealed tube. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and washed well with water. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was chromatographed on silica gel using hexane-ethyl acetate as the eluent to provide 6m (5.36 g, 98%) as a yellow oil. 1 The following compounds were obtained in the same manner as described in general procedure G.
3-Benzoyl-6-methyl-2-methylaminopyridine (6j): 84% yield; 7 mmol) in dichloroethane (30 ml) was added acetyl chloride (1.25 ml, 17.6 mmol) and 4-dimethylaminopyridine (1.17 g, 9.6 mmol), and the solution was stirred under reflux for 1 h. The reaction mixture was allowed to cool to room temperature and subsequently washed with water, 1 N hydrochloric acid, and saturated sodium bicarbonate aqueous solution. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated to provide the crude N- [3-(3- 
fluorobenzoyl)-6-methyl-2-pyridyl]-N-ethylacetamide. To the N-[3-(3-fluorobenzoyl)-6-methyl-2-pyridyl]-N-eth-
ylacetamide was added ethanol (30 ml) and sodium ethoxide (220 mg,) and stirred under reflux for 30 min. The reaction mixture was allowed to cool to room temperature and diluted with chloroform. The organic layer was subsequently washed with 1 N hydrochloric acid, and saturated sodium bicarbonate aqueous solution, dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was chromatographed on silica gel using hexaneethyl acetate as the eluent to provide 7e (1.18 g, 95%). Recrystallization from ethyl acetate-diisopropyl ether provided an analytical sample as colorless minute prisms, mp 106-107°C. -4-(3-methoxyphenyl)-7-methyl-1,8-naphthyridin-2(1H)-one (7g 
1-Ethyl
In an atmosphere of argon, a 1.6 M n-butyllithium hexane solution (1.3 ml, 2.1 mmol) was added dropwise to a tetrahydrofuran solution (5 ml) of diisopropylamine (203 mg, 2 mmol) which had been cooled at Ϫ78°C. After the addition was complete, this solution was warmed to ϫ30°C, then cooled to Ϫ78°C and 7c (597 mg, 2 mmol) was slowly added dropwise and the solution was stirred for 15 min at the same temperature. Methyl iodide (1.3 ml, 2.1 mmol) was slowly added dropwise at Ϫ78°C and the solution was stirred for 30 min at same temperature. The reaction solution was mixed with water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. After removing the magnesium sulfate, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) and further recrystallized from hexane to give 7p (161 mg, 26%) as colorless crystals. mp 74-75°C. 3-Benzoyl-2-pivaroylaminopyridine (12) In an atmosphere of argon, a 1.69 M n-butyllithium hexane solution (43 ml, 73 mmol) was added dropwise to a tetrahydrofuran solution (60 ml) of 2-pivaroylaminopyridine (11, 61.1 g, 34 mmol) which was cooled at Ϫ78°C. After the addition was complete, this solution was warmed to 0°C and stirred for 2.5 h. Then, N-methoxy-Nmethylbenzamide (6.25 g, 38 mmol) was slowly added dropwise at Ϫ78°C, the solution was warmed to room temperature and stirred for 2 h. The reaction solution was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. After removing the magnesium sulfate, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform then chloroform-ethyl acetate) and further washed with diisopropyl ether to give 12 (5.70 g, 59%) as a solid. 1 
. tert-Butyl 3-(2-Pivaroylaminopyridin-3-yl)-3-hydroxy-3-phenylpropanate (13) In an atmosphere of argon, a 1.69 M n-butyllithium hexane solution (53 ml, 90 mmol) was added dropwise to an ether solution (150 ml) of diisopropylamine (9.61 g, 95 mmol) which was cooled at Ϫ78°C. After 15 min of stirring, an ether solution (20 ml) of tert-butyl acetate (10.5 g, 90.5 mmol) was slowly added dropwise. After 30 min of stirring, a tetrahydrofuran solution (20 ml) of 12 (12.0 g, 42.6 mmol) was added dropwise. After 30 min of stirring, the reaction mixture was warmed to room temperature and stirred for 5 h. The reaction solution was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate. After removing the magnesium sulfate, the resulting filtrate was concentrated under reduced pressure to give 13 (16.9 g, 100%) as an oil. Phenyl-1,8-naphthyridin-2(1H)-one (14) A mixture of 13 (2.09 g, 5.25 mmol), 3 N hydrochloric acid (10 ml), and dioxane (10 ml) was stirred under reflux for 3 d. The reaction mixture was allowed to cool to room temperature, mixed with water, and the aqueous layer was neutralized with a saturated sodium bicarbonate aqueous solution. N-3-Ethylphenyl 3-Phenyl-3-oxopropanamide (17) A mixture of 3-ethylaniline (5.00 g, 41 mmol), ethyl 3-phenyl-3-oxopropanate (9.50 g, 49 mmol), and pyridine (2 drops) in xylene (30 ml) was stirred under reflux for 72 h. The reaction mixture was concentrated under reduced pressure and diluted with 1 N hydrochloric acid. The aqueous layer was extracted with chloroform and the organic layer was washed with brine, and dried over anhydrous sodium sulfate. After removing the sodium sulfate, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to give 17 ( 
4-

7-Ethyl-4-phenylquinolin-2(1H)-one (18)
A mixture of diphosphorus pentoxide (15 g ) and phosphoric acid (15 ml) was stirred at 100°C for 15 min. Then, 17 (2.83 g, 10 mmol) was added to this solution, and the mixture was stirred at 100°C for 1 h. The reaction solution was poured onto ice water, the resulting precipitate was collected and dissolved in chloroform. The organic layer was subsequently washed with a 1 N sodium hydroxide aqueous solution and brine. After drying the organic layer with anhydrous sodium sulfate, the sodium sulfate was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform-ethyl acetate) to give 18 (2.35 g, 89%) as a syrup. 
1,7-Diethyl-4-phenylquinolin-2(1H)-one (19)
To a solution of 18 (2.30 g, 9 mmol) in dimethylformamide (100 ml) was added a sodium hydride/60% oil dispersion (450 mg, 112 mmol) and the mixture was stirred at 80°C for 30 min. To the reaction mixture was added ethyl iodide (2.90 g, 19 mmol) and then it was stirred for 1 h. The mixture was concentrated and diluted with water, and then extracted with chloroform. The organic layer was washed with brine and dried over anhydrous sodium sulfate. The sodium sulfate was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate) to give 19, (983 mg, 38%) as a syrup. 1 17) were prepared in our laboratory according to the reported methods.
Pharmacology
PDE Inhibitory Activity. Isolation of Human Peripheral Leukocytes
The leukocytes were isolated from the peripheral blood of healthy human volunteers. Physiological saline supplemented with 3% dextran was added to heparinized human peripheral blood, and the mixture was incubated for 40 min at 37°C to precipitate the erythrocytes. The supernatant after precipitation of the erythrocytes was recovered and washed once with PBS, and the pellet, which contained leukocytes, was resuspended in a buffer (pH 7.4) containing sodium chloride (140 mM), potassium chloride (5 mM), glucose (5 mM) and HEPES (10 mM).
Isolation of Human Peripheral Blood Mononuclear Cells (PBMC)
The suspended leukocytes were overlaid on a solution for density gradient centrifugation use Ficoll ® solution, and then centrifuged at room temperature for 40 min at 450 g, thereby separating the mononuclear cells and granulocytes. The mononuclear cell fraction was washed once and resuspended in RPMI with 10% FBS.
Purification of PDE Isozyme PDE2, PDE3, PDE4, and PDE5 were prepared from human peripheral leukocytes, and PDE1 was prepared from rat ventricles. All the enzymes were partially purified by Q Sepharose Fast Flow (Pharmacia Biotech, Sweden) with 0.05 to 1.25 M sodium acetate gradients from the 100000ϫg supernatants. The following protease inhibitors
